TICKERNERD
Menu
CCCCCCCCHealthcare · Biotechnology

CCCC Stock Forecast: C4 Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$2.85
+1.06% on the day

The 7 Wall Street analysts covering C4 Therapeutics, Inc. hold a median 12-month price target of $11 — +286.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 69 of 100 as at 8 Oct 2026 — in the upper half.

Market cap
$354.3M
Ticker Nerd rank
69 / 100
Median analyst target
$11
Analysts covering
7
Revenue$6.6M+2.8% y/y
Operating income−$26.4M
Net income−$23.6M
Free cash flow−$1.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.2%
1M
−19.7%
YTD
+49.2%
1Y
+27.8%
From 52W high
−39.0%
From 52W low
+66.7%
$1.71
$4.67
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CCCC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores C4 Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
69 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
91
Revisions
88
Momentum
61
Size
58
Quality
48
Accruals
46
Issuance
45
Value
42
Volatility
17

Growth (91): Sales and profits are climbing, and climbing faster than before.

Volatility (17): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CCCC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CCCC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00$30.00$35.00Jan 26Apr 26Jul 26Oct 26CCCCHigh $30Median $11Low $7

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $7Median $11High $30

The green dot is the last close — the median target sits +286.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
1 June 2026Evercore ISI GroupMaintainsOutperform$7.00 → $12
27 Feb 2026BarclaysMaintainsOverweight—
23 Feb 2026Brookline CapitalMaintainsBuy—
17 Dec 2025BarclaysMaintainsOverweight—
2 Dec 2025TD CowenInitiatesBuy—
23 Sept 2025BarclaysMaintainsOverweight—
23 Sept 2025Wells FargoMaintainsOverweight—
22 Sept 2025Stephens & Co.ReiteratesOverweight—
17 Sept 2025BarclaysInitiatesOverweight—
15 Sept 2025Stephens & Co.UpgradeOverweight—
4 Sept 2025GuggenheimInitiatesBuy—
19 Dec 2024Wells FargoUpgradeOverweight—
18 Nov 2024Stephens & Co.InitiatesEqual-Weight—
6 Aug 2024BMO CapitalReiteratesOutperform—
9 May 2024StifelMaintainsBuy—
9 May 2024Wells FargoMaintainsEqual-Weight—
26 Feb 2024Morgan StanleyMaintainsEqual-Weight—
23 Feb 2024StifelReiteratesBuy—
29 Jan 2024JP MorganUpgradeNeutral—
13 Dec 2023StifelUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CCCC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CCCC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, C4 Therapeutics, Inc. returned +27.8% against +16.2% for the S&P 500, dividends included.

CCCC vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Jan 26Apr 26Jul 26Oct 26CCCCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CCCC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

C4 Therapeutics, Inc. (CCCC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.3×

Cheaper than 86% of US stocks

Price / sales
10.1×

Cheaper than 14% of US stocks

Price / book
1.4×

Cheaper than 55% of US stocks

EV / EBITDA
−1.6×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
2.8%

Higher than 34% of US stocks

Earnings growth (YoY)
2.8%

Higher than 39% of US stocks

Gross margin
—
Operating margin
−397.9%

Higher than 8% of US stocks

Net margin
−289.4%

Higher than 1% of US stocks

Returns & dividend
Return on equity
−48.1%

Higher than 22% of US stocks

Return on assets
−19.3%

Higher than 20% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

C4 Therapeutics, Inc. (CCCC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • C4 Therapeutics, Inc. has a market value of $354.3M and an enterprise value of $157.5M.

  • Revenue in the twelve months to 30 June 2026: $35.0M. The latest quarter grew 2.8% year on year.

  • Net income over the same four quarters: −$101.4M, a −289.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.00.

  • Free cash flow in the twelve months to 30 June 2026: −$85.4M.

  • C4 Therapeutics, Inc. spent $238K on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 122.9M.

  • Trailing P/E: −2.3×; forward P/E: −2.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • C4 Therapeutics, Inc. employs 104 people — $337K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

CCCC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CCCCC4 Therapeutics, Inc.$354.3M
69
ENTAEnanta Pharmaceuticals, Inc.$352.4M
90
SCTXScribe Therapeutics, Inc.$362.8M
2
IRDOpus Genetics, Inc.$363.0M
60
INDPIndaptus Therapeutics, Inc.$364.0M
25
AGENAgenus, Inc.$337.4M
87
ARCTArcturus Therapeutics Holdings, Inc.$365.7M
69

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own C4 Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CCCC news & analysis

C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting

GlobeNewsWire · 25 Sept 2026positive

C4 Therapeutics presented new biomarker data from its Cemsidomide Phase 1 trial with dexamethasone and Phase 1b trial with elranatamab in relapsed/refractory multiple myeloma at the 23rd International Myeloma Society Annual Meeting. The data demonstrated robust T-cell activation, a key component of cemsidomide's dual mechanism of action.

Why it matters — This presentation provides evidence supporting cemsidomide's mechanism of action in treating relapsed/refractory multiple myeloma, offering C4 Therapeutics watchers insight into the drug's clinical development progress.

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

Zacks Investment Research · 23 Sept 2026neutral

This Zacks Investment Research article compares how C4 Therapeutics (CCCC) and MacroGenics (MGNX) have performed against their sector so far this year, framing the question of whether medical stocks are lagging C4 Therapeutics.

Why it matters — A C4 Therapeutics watcher would use this comparison to gauge how the company's year-to-date performance stacks up against both a peer and its broader sector.

C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting

GlobeNewsWire · 3 Sept 2026positive

C4 Therapeutics announced that new biomarker data on the immunomodulatory effects of cemsidomide in combination with dexamethasone from its Phase 1 relapsed/refractory multiple myeloma trial will be presented in a poster at the 23rd International Myeloma Society (IMS) Annual Meeting. The announcement was made on September 3, 2026, from the company's headquarters in Watertown, Massachusetts.

Why it matters — This announcement signals progress in C4 Therapeutics' lead clinical program for cemsidomide targeting relapsed/refractory multiple myeloma, and presenting data at a major industry conference could help raise visibility and credibility for the company's drug candidate.

Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice

Zacks Investment Research · 21 Aug 2026positive

Zacks Investment Research published a piece examining whether C4 Therapeutics, Inc. (CCCC) qualifies as a top momentum pick for investors. The article poses the question of whether the stock has what it takes to be selected for momentum-focused strategies.

Why it matters — C4 Therapeutics watchers would care because the article highlights the company's stock as a candidate for momentum investing, potentially drawing increased attention to CCCC.

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 11 Aug 2026positive

C4 Therapeutics reported a Q2 loss of $0.18 per share, narrower than the Zacks Consensus Estimate of a $0.23 loss and an improvement from the $0.37 loss reported in the same quarter last year. Revenue exceeded analyst expectations.

Why it matters — The smaller-than-expected quarterly loss and revenue beat suggest the company's financial performance is improving relative to analyst projections.

FAQ

Frequently asked questions about CCCC stock

What is the CCCC stock price forecast for 2026-2027?

The 7 Wall Street analysts covering C4 Therapeutics, Inc. have a median 12-month price target of $11, with estimates ranging from $7 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CCCC stock a buy right now?

Of the 7 analysts covering C4 Therapeutics, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks C4 Therapeutics, Inc. 69 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CCCC?

As at 8 Oct 2026, C4 Therapeutics, Inc. ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (91 of 100).

Will CCCC stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +286.0% from the last close, and Ticker Nerd's factor model ranks C4 Therapeutics, Inc. 69 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CCCC stock forecast for 2030?

No analyst covering C4 Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CCCC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $30 over the next 12 months.

How has CCCC stock performed over the past year?

C4 Therapeutics, Inc. returned +27.8% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does C4 Therapeutics, Inc. do?

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation, a drug-development approach designed to eliminate disease-causing proteins rather than only blocking their activity.

What is the latest news on CCCC?

The most recent item we track (GlobeNewsWire, 25 Sept 2026): "C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting". C4 Therapeutics presented new biomarker data from its Cemsidomide Phase 1 trial with dexamethasone and Phase 1b trial with elranatamab in relapsed/refractory multiple myeloma at the 23rd International Myeloma Society Annual Meeting. The data demonstrated robust T-cell activation, a key component of cemsidomide's dual mechanism of action.

Company

About C4 Therapeutics, Inc.

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation, a drug-development approach designed to eliminate disease-causing proteins rather than only blocking their activity. The company develops small-molecule medicines built on its proprietary TORPEDO platform, which is used to design and optimize degraders for difficult-to-treat diseases. Its current pipeline is centered on oncology, with programs aimed at cancers such as multiple myeloma, lymphoma, melanoma, colorectal cancer, and non-small cell lung cancer. C4 Therapeutics also works through strategic collaborations with other biopharmaceutical companies to expand the reach of its technology and advance new therapeutic candidates. Based in Watertown, Massachusetts, C4 Therapeutics plays a specialized role in the biotechnology market by advancing a next-generation therapeutic modality that seeks to address targets and pathways not readily handled by traditional small-molecule drugs.

CEO Mr. Andrew J. Hirsch M.B.A. · 104 employees · United States · https://www.c4therapeutics.com